05:06 PM EDT, 06/09/2025 (MT Newswires) -- Merck ( MRK ) said Monday the US Food and Drug Administration has approved Enflonsia for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, Merck ( MRK ) said.